Reported Standalone quarterly numbers for JB Pharma are:
Story continues below Advertisement
Net Sales at Rs 955.76 crore in September 2024 up 14.22% from Rs. 836.76 crore in September 2023.
Quarterly Net Profit at Rs. 173.12 crore in September 2024 up 19.38% from Rs. 145.02 crore in September 2023.
EBITDA stands at Rs. 277.07 crore in September 2024 up 14.64% from Rs. 241.68 crore in September 2023.
Story continues below Advertisement
JB Pharma EPS has increased to Rs. 11.15 in September 2024 from Rs. 9.36 in September 2023.
JB Pharma shares closed at 1,880.70 on November 05, 2024 (NSE) and has given 1.48% returns over the last 6 months and 33.04% over the last 12 months.
| JB Pharma | | Standalone Quarterly Results | in Rs. Cr. |
|
| Sep'24 | Jun'24 | Sep'23 | | Net Sales/Income from operations | 955.76 | 952.31 | 836.76 | | Other Operating Income | -- | -- | -- | | Total Income From Operations | 955.76 | 952.31 | 836.76 | | EXPENDITURE | | Consumption of Raw Materials | 179.22 | 251.67 | 221.36 | | Purchase of Traded Goods | 139.14 | 79.21 | 60.79 | | Increase/Decrease in Stocks | 5.49 | -8.19 | -0.66 | | Power & Fuel | -- | -- | -- | | Employees Cost | 160.46 | 156.67 | 141.44 | | Depreciation | 40.85 | 40.01 | 31.50 | | Excise Duty | -- | -- | -- | | Admin. And Selling Expenses | -- | -- | -- | | R & D Expenses | -- | -- | -- | | Provisions And Contingencies | -- | -- | -- | | Exp. Capitalised | -- | -- | -- | | Other Expenses | 203.27 | 199.57 | 178.99 | | P/L Before Other Inc. , Int., Excpt. Items & Tax | 227.33 | 233.37 | 203.34 | | Other Income | 8.89 | 5.16 | 6.84 | | P/L Before Int., Excpt. Items & Tax | 236.22 | 238.53 | 210.18 | | Interest | 2.02 | 4.32 | 9.46 | | P/L Before Exceptional Items & Tax | 234.20 | 234.21 | 200.72 | | Exceptional Items | -- | -- | -- | | P/L Before Tax | 234.20 | 234.21 | 200.72 | | Tax | 61.08 | 60.98 | 55.70 | | P/L After Tax from Ordinary Activities | 173.12 | 173.23 | 145.02 | | Prior Year Adjustments | -- | -- | -- | | Extra Ordinary Items | -- | -- | -- | | Net Profit/(Loss) For the Period | 173.12 | 173.23 | 145.02 | | Equity Share Capital | 15.53 | 15.52 | 15.50 | | Reserves Excluding Revaluation Reserves | -- | -- | -- | | Equity Dividend Rate (%) | -- | -- | -- | | EPS Before Extra Ordinary | | Basic EPS | 11.15 | 11.16 | 9.36 | | Diluted EPS | 10.92 | 10.94 | 9.19 | | EPS After Extra Ordinary | | Basic EPS | 11.15 | 11.16 | 9.36 | | Diluted EPS | 10.92 | 10.94 | 9.19 | | Public Share Holding | | No Of Shares (Crores) | -- | -- | -- | | Share Holding (%) | -- | -- | -- | | Promoters and Promoter Group Shareholding | | a) Pledged/Encumbered | | - Number of shares (Crores) | -- | -- | -- | | - Per. of shares (as a % of the total sh. of prom. and promoter group) | -- | -- | -- | | - Per. of shares (as a % of the total Share Cap. of the company) | -- | -- | -- | | b) Non-encumbered | | - Number of shares (Crores) | -- | -- | -- | | - Per. of shares (as a % of the total sh. of prom. and promoter group) | -- | -- | -- | | - Per. of shares (as a % of the total Share Cap. of the company) | -- | -- | -- | | Source : Dion Global Solutions Limited |
|
Discover the latest Business News, Sensex, and Nifty updates. Obtain Personal Finance insights, tax queries, and expert opinions on Moneycontrol or download the Moneycontrol App to stay updated!
